¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°£¾ÏÇÐȸ APPLE 2023 (The 13th Asia-Pacific Primary Liver Cancer Expert Meeting) - Day2 : 2023-07-07

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑ°£¾ÏÇÐȸ APPLE 2023 (The 13th Asia-Pacific Primary Liver Cancer Expert Meeting) - Day2 : 2023-07-07
±³À°ÀÏÀÚ : 2023-07-07
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 ¿Ü 1°³·ë

±³À°ÁÖÁ¦ : APPLE 2023 (The 13th Asia-Pacific Primary Liver Cancer Expert Meeting) - Day2

ÁÖÃÖ±â°ü : ´ëÇÑ°£¾ÏÇÐȸ
´ã´çÀÚ : Ȳ¼öÁ¤
¿¬¶ôó : 02-373-1005  

À̸ÞÀÏ : apple2023@hbni.co.kr

±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú

Âü¼®¿¹»óÀÎ : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 300,000¿ø  

ºñ°í [Regular Registration-Non-Member Rate] Doctor, Healthcare Professionals: KRW 300,000 / USD 300 Fellow, Resident, Researcher, Others: KRW 250,000 / USD 250 Poster Presenter: KRW 100,000 / USD 100 [Regular Registration-Member Rate] Doctor, Healthcare Professionals: KRW 250,000 / USD 250 Fellow, Resident, Researcher, Others: KRW 200,000 / USD 200 Poster Presenter: KRW 100,000 / USD 100


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 08:30~08:50 Current Status of HCC Surveillance: Barriers, Gaps, and Need for Improvement Morris Sherman(Univ. of Toronto, Toronto)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 08:50~09:10 Emerging Imaging Tools for HCC Surveillance: Benefits and Concerns Kengo Yoshimitsu(Fukuoka Univ., Fukuoka)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 09:10~09:30 Diagnostic Strategy and Risk Stratification of Borderline Nodules on Imaging Jeong Min Lee(Seoul National Univ.)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 09:30~09:50 Developing Biomarkers for Early Detection of HCC Stephen Lam Chan(The Chinese Univ. of Hong Kong, Hong Kong)

Åä·Ð 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 09:50~10:00 Discussion Morris Sherman, Kengo Yoshimitsu, Jeong Min Lee, Stephen Lam Chan(Univ. of Toronto, Toronto, Fukuoka Univ., Fukuoka, Seoul National Univ., The Chinese Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 10:20~10:50 When We Should Consider the Biopsy for Diagnosis, Subtyping, and Prognostication of Primary Liver Cancer: Radiologist¡¯s Perspective Kathryn J. Fowler(Univ. of California San Diego, San Diego)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 11:00~11:20 Advances in Surgical Management and Evolving Techniques Pierce Chow(National Cancer Centre, Singapore)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 11:20~11:40 Local Ablation: What is New in 2023? Hyunchul Rhim (Sungkyunkwan Univ.)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 11:40~12:00 Ablative Radiotherapy for Early HCC Jason Cheng(National Taiwan Univ., Taipei)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 12:00~12:20 Role of Transarterial Therapy in Early HCC Hyo-Cheol Kim (Seoul National Univ.)

Åä·Ð 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 12:20~12:30 Discussion Pierce Chow, Hyunchul Rhim, Jason Cheng, Hyo-Cheol Kim (National Cancer Centre, Singapore, Sungkyunkwan Univ., National Taiwan Univ., Taipei, Seoul National Univ.)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 13:30~14:00 Evolution of APPLE and Liver Cancer Management Norihiro Kokudo(National Center for Global Health and Medicine, Tokyo)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 14:00~14:20 Looking into the Intermediate-Stage HCC: Ongoing Effort towards Creating a Subclassification Fabio Piscaglia(Univ. of Bologna, Bologna)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 14:20~14:40 Expanding the Role of Surgical Resection and Transplantation in Intermediate-Stage HCC Albert Chan(The Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 14:40~15:00 To What Extent Can TARE Replace the Role of TACE in the Intermediate-Stage HCC? Edward Kim(Icahn School of Medicine at Mount Sinai, New York)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 15:00~15:20 The Potential Role of Systemic Therapy in Intermediate-Stage HCC: A Paradigm Shift? Masatoshi Kudo(Kindai Univ., Osaka)

Åä·Ð 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 15:20~15:30 Discussion Norihiro Kokudo, Fabio Piscaglia, Albert Chan, Edward Kim, Masatoshi Kudo(National Center for Global Health and Medicine, Tokyo, Univ. of Bologna, Bologna,The Univ. of Hong Kong, Hong Kong, Icahn School of Medicine at Mount Sinai, New York, Kindai Univ., Osaka)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 15:50~16:20 Systemic Therapies for HCC: Expanding Indications Ghassan Abou-Alfa(Weill Cornell College at Cornell Univ., New York)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 08:30~08:50 Deciphering the Immune and Vascular Microenvironment of HCC Michiie Sakamoto(Keio Univ., Tokyo)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 08:50~09:10 Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer Xin Wei Wang(National Institutes of Health, Bethesda)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 09:10~09:30 Recreating Tumor Complexity in a Dish: Patient-Derived Cancer Organoids Stephanie Ma(The Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 09:30~09:50 Spatial Heterogeneity and Immune Evasion Mechanism of Circulating Tumor Cells in HCC Xin-Rong Yang(Fudan Univ, Shanghai)

Åä·Ð 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 09:50~10:00 Discussion Michiie Sakamoto, Xin Wei Wang, Stephanie Ma, Xin-Rong Yang(Keio Univ., Tokyo, National Institutes of Health, Bethesda, The Univ. of Hong Kong, Hong Kong, Fudan Univ, Shanghai)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 10:20~10:50 When We Should Consider the Biopsy for Diagnosis, Subtyping, and Prognostication of Primary Liver Cancer: Radiologist¡¯s Perspective Kathryn J. Fowler(Univ. of California San Diego, San Diego)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 11:00~11:20 Prevention of HBV-Related HCC: Antiviral Therapy Young-Suk Lim(Univ. of Ulsan)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 11:20~11:40 Balancing the Risk and Benefit of Long-Term Antiviral Therapy for HBV Wai-Kay Seto(The Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 11:40~12:00 Latest Update of Direct-Acting Antiviral Treatment for HCV Eiichi Ogawa(Kyushu Univ., Fukuoka)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 12:00~12:20 Impact of Direct-Acting Antiviral Therapy on HCC: Occurrence, Recurrence, and Prognosis Hyung Joon Yim(Korea Univ.)

Åä·Ð 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 12:20~12:30 Discussion Young-Suk Lim, Wai-Kay Seto, Eiichi Ogawa, Hyung Joon Yim(Univ. of Ulsan, The Univ. of Hong Kong, Hong Kong, Kyushu Univ., Fukuoka, Korea Univ.)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 13:30~14:00 Evolution of APPLE and Liver Cancer Management Norihiro Kokudo(National Center for Global Health and Medicine, Tokyo)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 14:00~14:20 The Era of Diversity: Does Conventional TACE Still Work? Jin Wook Chung(Seoul National Univ.)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 14:20~14:40 Technical issues in TACE: Focusing on Korean Recommendation In Joon Lee(National Cancer Center)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 14:40~15:00 Role of Surgical Resection for HCC with Portal Vein Tumor Thrombosis Jia Fan (Fudan Univ., Shanghai)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 15:00~15:20 Integration of Systemic and Locoregional Therapy Joong-Won Park(National Cancer Center)

Åä·Ð 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 15:20~15:30 Discussion Jin Wook Chung, In Joon Lee, Jia Fan, Joong-Won Park(Seoul National Univ., National Cancer Center, Fudan Univ., Shanghai, National Cancer Center)

±³À°½Ã°£ 07¿ù 07ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 15:50~16:20 Systemic Therapies for HCC: Expanding Indications Ghassan Abou-Alfa(Weill Cornell College at Cornell Univ., New York)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°£¾ÏÇÐȸ APPLE 2023 (The 13th Asia-Pacific Primary Liver Cancer Expert Meeting) - Day2 : 2023-07-07""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â Áß¾Ó´ëÇб³º´¿ø ÅÂ¾Æ ½ÉÀåÃÊÀ½ÆÄ ¿¬¼Ó°­Á 4°­ : 2023-07-07
´ÙÀ½±Û (¿Â¶óÀÎ) Á¦ 5ȸ °¡Å縯´ëÇб³ ¼ººó¼¾Æ® ¾Ïº´¿ø ½ÉÆ÷Áö¾ö : 2023-07-07
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 34 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 34 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 30 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 26 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 30 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 41 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 17 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 23 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 22 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 22 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 21 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 19 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 22 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 25 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 26 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷